Navigation Links
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Date:10/31/2012

ents that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates and research and clinical programs now underway or planned, including without limitation SAR236553/REGN727, unforeseen safety issues resulting from the administration of products and product candidates in patients, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and drug candidates, competing drugs that may be superior to Regeneron's products and drug candidates, uncertainty of market acceptance of Regeneron's products and drug candidates, unanticipated expenses,  the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2011 and its Form 10-Q for the quarter ended September 30, 2012.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Contacts:Sanofi:Media RelationsInvestor RelationsMarisol Per
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur to add 2D barcode to six more vaccines
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
4. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
5. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
6. Regeneron Announces September 2012 Investor Conference Presentations
7. Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
8. Regeneron Announces June 2012 Investor Conference Presentations
9. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
10. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
11. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market ... Scanner Industry, 2009-2019 is a professional and in-depth ... Crystallography Scanner industry . The report firstly reviews ... its classification, application and manufacturing technology. The report ... X-Ray Crystallography Scanner listing their product specification, capacity, ...
(Date:8/29/2014)... 2014  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), ... support services for the lawfully organized cannabis industry, ... approved the Company,s name and symbol change request. ... be known as Chuma Holdings, Inc. ... merger with the Company,s wholly-owned subsidiary, Chuma Holdings, ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... SAN DIEGO, Oct. 2 Pharmatek Laboratories, Inc., a ... industry, announced that it is the first CRO on ... the company,s preclinical and early phase clinical GMP supply ... move our customers, drug candidates into the clinic more ...
... The next major personalized medicine advances will create therapies that ... health care industry to gain access, the inventor of the ... Medical Center,s Personalized Health Care National Conference ... for Systems Biology, said personalized medicine,s first "killer apps" - ...
Cached Medicine Technology:Pharmatek Laboratories Announces Acquisition of the First Xcelodose(R) 600S System on the West Coast 2Personalized Medicine 'Killer Apps' Will Transform Care Model 2
(Date:8/29/2014)... As reported by GantDaily.com in the article ... , Outbreaks (8/20), the National Institute on Drug Abuse is ... trends by turning to social media. As NIDA currently relies ... also working with the University of Maryland to create a ... which will be funded by the National Institute of Health. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by the ... By Drug Court Grad (8/17), a graduate of the Frederick ... back after his own experience with the program. The graduate, Korey ... also includes a 1 mile walk. He plans to donate the ... well as to those who helped him. Shorb, who graduated in ...
(Date:8/29/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Glass microfiber including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... G. Rodas. Dr. Rodas will be practicing out of ... As a member of Healthpointe’s orthopedic team, ... internal medicine, and board-certified in occupational medicine. , ... title as Medical Director of Raytheon, the world-class defense ...
(Date:8/29/2014)... Dr. Parsa Mohebi M.D. has developed new techniques ... great results in hair transplantation. One of these techniques ... FUE method that harvests facial hair for transplanting to the ... whose hair loss classification is 5 and above achieve reasonable ... alternative for those advanced hair loss patients who may not ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2
... ... Open in Late 2008, BETHESDA, Md., Feb. 19 Fox ... Living, Inc. (NYSE: SRZ ), continues to thrive during one ... already,been reserved to date and construction on the community is at ...
... revolution taking place,and it,s changing the face of cold-beverage ... that,s more sophisticated than traditional,sodas. Many are looking for ... past, finding a healthy and delicious bottled,drink was no ... are,definitely something to get excited about., "The beverage ...
... CHARLOTTE, N.C., Feb. 19 MedCath Corporation,(Nasdaq: ... has entered into,a new strategic relationship with Solaris ... LLC, will participate in a new venture to ... hospitals, JFK,Medical Center and Muhlenberg Regional Medical Center. ...
... 19 With Presidential,candidates campaigning -- and smiling ... Michael Kosdon has had ample opportunity to,judge their ... has,picked a winner., "I would definitely say ... than Hillary Clinton," says Kosdon, who has,transformed hundreds ...
... Inc., the worldwide leader,in handheld X-ray technologies, today ... available. The NOMAD Pro builds upon,the heritage of ... http://www.newscom.com/cgi-bin/prnh/20080219/LATU057 ), "The NOMAD has forever changed ... an operator to safely stay in the room ...
... medication, error prevention outreach and education for HIMSS attendees wearing custom ... ... BRUNO, Calif., Feb. 19 First DataBank, a leading,provider of drug ... to focus public and industry attention on the,prevention of medication errors. ...
Cached Medicine News:Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 2Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 3Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 4Health News:The Search for Healthier Drinks Turns Up Yerba Mate 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 3Health News:Smiling on the Campaign Trail - Cosmetic Dentist Michael Kosdon Rates the Candidates 2Health News:Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 3
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
... II (Low Melt), A low temperature ... melting temperature , Optimal for in-gel restriction ... forms a very manageable clear gel that ... Melts at approximately 65°C and remains fluid ...
... Agarose, Molecular Biology Grade, is ... of nucleic acids. It can ... fragments from 0.2 to 40 ... Agarose is tested and certified ...
Medicine Products: